HC Wainwright Brokers Decrease Earnings Estimates for BHST

BioHarvest Sciences Inc. (NASDAQ:BHST) – HC Wainwright reduced their Q2 2026 earnings per share estimates for BioHarvest Sciences in a research note issued on Friday, May 15th. HC Wainwright analyst A. Dayal now expects that the company will post earnings of ($0.14) per share for the quarter, down from their prior estimate of ($0.09). The consensus estimate for BioHarvest Sciences’ current full-year earnings is ($0.35) per share. HC Wainwright also issued estimates for BioHarvest Sciences’ Q3 2026 earnings at ($0.13) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.46) EPS, FY2027 earnings at ($0.16) EPS and FY2029 earnings at $0.83 EPS.

BioHarvest Sciences (NASDAQ:BHST) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.02. BioHarvest Sciences had a negative return on equity of 102.36% and a negative net margin of 32.54%.The business had revenue of $8.51 million for the quarter, compared to the consensus estimate of $8.50 million.

Other research analysts also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioHarvest Sciences in a research note on Friday, March 27th. Roth Mkm initiated coverage on BioHarvest Sciences in a research note on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price on the stock. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $10.00.

BioHarvest Sciences Stock Performance

Shares of NASDAQ BHST opened at $3.96 on Tuesday. The business’s 50-day moving average price is $4.25 and its two-hundred day moving average price is $5.21. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.97 and a quick ratio of 3.38. BioHarvest Sciences has a one year low of $3.57 and a one year high of $12.80. The company has a market capitalization of $77.68 million, a P/E ratio of -6.71 and a beta of 0.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Alyeska Investment Group L.P. bought a new stake in shares of BioHarvest Sciences during the 4th quarter worth about $3,929,000. Thompson Siegel & Walmsley LLC bought a new stake in shares of BioHarvest Sciences during the 4th quarter worth about $1,945,000. True North Advisors LLC boosted its stake in shares of BioHarvest Sciences by 381.0% during the 1st quarter. True North Advisors LLC now owns 168,013 shares of the company’s stock worth $729,000 after acquiring an additional 133,085 shares in the last quarter. Evercore Wealth Management LLC bought a new stake in shares of BioHarvest Sciences during the 4th quarter worth about $724,000. Finally, King Luther Capital Management Corp bought a new stake in shares of BioHarvest Sciences during the 4th quarter worth about $208,000.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.